Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
|Articles|April 18, 2022
The Mainstream Patient: April 18
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about the causes of eczema, botox for TMJ, and more.
Advertisement
In this week’s edition, Self highlights the causes of eczema and InStyle tells the story of a patient getting botox for their TMJ. Cosmopolitan dives into hair removal and Glamour interviews Zenovia Gabriel, MD, about her acne journey. Elle exlpores clean beuty skin care and Allure talks Daxi.
Here’s the Truth About What Causes Eczema
I Get Botox for My TMJ, And It's the Best Thing I've Done for Pain Relief
How to Remove Facial Hair: 17 Best Facial Hair Removal Products for Smooth Skin 2022
Dr. Zenovia Says Cystic Pregnancy Acne Made Her a Better Derm
"Cleanical" Skincare Is The Future Of Clean Beauty
What's the Deal With Daxi, the New Neurotoxin Everyone's Talking About?
Advertisement
Related to this article
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
5